William Collins > Goodwin > Boston, United States > Lawyer Profile
Goodwin Offices
100 NORTHERN AVENUE
BOSTON MA 02210
MASSACHUSETTS
United States
- Firm Profile
- Go to...
William Collins
Position
Partner
Career
William Collins is a partner in Goodwin’s nationally recognized Life Sciences group, counseling clients in the industries of biotechnology, pharmaceuticals and medical devices. Serving as his clients’ principal outside counsel, William provides strategic advice and corporate legal counseling to management teams and boards while structuring and leading significant transactions on his clients’ behalf. He is recognized by his clients and colleagues for his extensive industry knowledge and deal experience, and for providing practical legal and business advice. William has also been recognized as one of Law360’s Rising Stars for 2022.
William has extensive experience with startup and formation matters, venture capital financings, initial public offerings, deSPAC transactions and other equity debt capital markets transactions, mergers and acquisitions, strategic collaborations, and other complex transactions. He also represents a number of publicly traded biotechnology companies in ongoing SEC compliance, capital raising and corporate governance matters.
William has advised many of his clients through their full corporate life cycle, starting with their initial founding and funding. He also regularly represents leading venture capital firms focused on the life sciences industry in connection with their portfolio company investments, exits and secondary stock sale transactions.
Education
JD, 2009, Boston University School of Law (cum laude) / BS, 2006, The University of Texas at Dallas (cum laude)
Lawyer Rankings
United States > M&A/corporate and commercial > Venture capital and emerging companies
(Next Generation Partners)Goodwin has a top tier venture capital practice, noted for its ‘very professional, knowledgeable and responsive’ teams of lawyers who are ‘real partners in growing the business‘. The ‘very business oriented, extremely practical‘ group offers ‘expert legal advice‘ to investors and startups, and stands out for its market-leading life sciences group, primarily based in the firm’s Boston office and co-chaired by Mitchell Bloom and Kingsley Taft. The firm’s ability to guide clients from early financing rounds through to later stage M&A, can be seen through its advice to Navitor Pharmaceuticals on the sale of Anakuria Therapeutics to Janssen Pharmaceuticals – a deal led by Danielle Lauzon, co-chair of the firm’s PropSci practice. The firm’s technology group, jointly led by Kenneth Gordon and Silicon Valley’s Anthony McCusker, has also played a key role on investments into digital health, fintech, mobility tech and blockchain. Other lead partners include Bill Schnoor on the technology side and William Collins in life sciences. All partners based in Boston unless otherwise stated.
Lawyer Rankings
- Next Generation Partners United States > M&A/corporate and commercial > Venture capital and emerging companies
- Venture capital and emerging companies United States > M&A/corporate and commercial
Top Tier Firm Rankings
- Finance > Financial services regulation
- Industry focus > Cannabis
- Intellectual property > Patents: licensing
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Industry focus > Education
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- Dispute resolution > Securities litigation: defense
- Finance > Capital markets: debt offerings
- International Trade > CFIUS
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > E-discovery
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Real estate > Real estate
- M&A/corporate and commercial > Shareholder activism
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- Labor and employment > Employee benefits, executive compensation and retirement plans: design
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Healthcare > Service providers
- International Trade > Customs, export controls and economic sanctions
- Dispute resolution > Leading trial lawyers
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)